<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37607754</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e200153</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000200153</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Anti-IgLON5 disease (IgLON5-D) may present with a bulbar-onset motor neuron disease-like phenotype, mimicking bulbar-onset amyotrophic lateral sclerosis. Recognition of their distinctive clinical and paraclinical features may help for differential diagnosis. We report 2 cases of atypical trigeminal neuropathy in bulbar-onset IgLON5-D.</AbstractText><AbstractText Label="METHODS">Trigeminal nerve involvement was assessed using comprehensive clinical, laboratory, electrophysiologic, and MRI workup.</AbstractText><AbstractText Label="RESULTS">Both patients were referred for progressive dysphagia, sialorrhea, and hoarseness. They were treated with bilevel positive airway pressure for nocturnal hypoventilation. Patient 1 complained of continuous facial burning pain with allodynia, exacerbated by mastication and prolonged speech. Patient 2 reported no facial pain. Anti-IgLON5 autoantibodies (IgLON5-Abs) were positive in serum for both patients and CSF for patient 1. Cerebral MRI revealed bilateral T2 fluid-attenuated inversion recovery (FLAIR) hyperintensity and enlargement of trigeminal nerves without gadolinium enhancement in both patients. Needle myography showed fasciculations in masseter muscles. Blink-reflex study confirmed bilateral trigeminal neuropathy only in patient 2. Cortical laser-evoked potentials showed a bilateral small-fiber dysfunction in the trigeminal nerve ophthalmic branch in patient 1.</AbstractText><AbstractText Label="DISCUSSION">In case of progressive atypical bulbar symptoms, the presence of a trigeminal neuropathy or trigeminal nerve abnormalities on MRI should encourage the testing of IgLON5-Abs in serum and CSF.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cluse</LastName><ForeName>Florent</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6781-7395</Identifier><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France. florent.cluse@chu-lyon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermier</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demarquay</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogemond</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-2098-920X</Identifier><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallaret</LastName><ForeName>Martial</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svahn</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegat</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1563-9432</Identifier><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honnorat</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Emilien</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3952-9265</Identifier><AffiliationInfo><Affiliation>From the ALS Resource and Competence Center (F.C., J.S., A.P., E.B.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Electroneuromyography and Neuromuscular Diseases Unit (F.C.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Department of Neuroradiology (M.H.), Pierre Wertheimer Hospital, Hospices Civils de Lyon; Neurophysiology &amp; Epilepsy Unit (G.D.), Neurological Hospital P. Wertheimer, Hospices Civils de Lyon; Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (V.R., J.H.), Hospices Civils de Lyon, Neurological Hospital, Bron; and Centre de Comp&#xe9;tences des Maladies Neuro Musculaires (M.M.), CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>AU0V1LM3JT</RegistryNumber><NameOfSubstance UI="D005682">Gadolinium</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C535841">Hashimoto's encephalitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005682" MajorTopicYN="N">Gadolinium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014276" MajorTopicYN="N">Trigeminal Nerve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020433" MajorTopicYN="Y">Trigeminal Nerve Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no relevant disclosures. Go to Neurology.org/NN for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37607754</ArticleId><ArticleId IdType="pmc">PMC10584367</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000200153</ArticleId><ArticleId IdType="pii">10/6/e200153</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sabater L, Gaig C, Gelpi Eet al. . A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13(6):575-586. doi. 10.1016/S1474-4422(14)70051-1. Erratum in: Lancet Neurol. 2015;14(1):28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70051-1</ArticleId><ArticleId IdType="pmc">PMC4104022</ArticleId><ArticleId IdType="pubmed">24703753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaig C, Graus F, Compta Y, et al. . Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736-1743. doi. 10.1212/WNL.0000000000003887</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003887</ArticleId><ArticleId IdType="pmc">PMC5409845</ArticleId><ArticleId IdType="pubmed">28381508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelpi E, H&#xf6;ftberger R, Graus F, et al. . Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132(4):531-543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5023728</ArticleId><ArticleId IdType="pubmed">27358064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabater L, Planagum&#xe0; J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226. doi. 10.1186/s12974-016-0689-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0689-1</ArticleId><ArticleId IdType="pmc">PMC5007989</ArticleId><ArticleId IdType="pubmed">27586161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y, Shen D, Zhang Y, et al. . Expanding the clinical spectrum of anti-IgLON5 disease: a multicenter retrospective study. Eur J Neurol. 2022;29(1):267-276. doi. 10.1111/ene.15117</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15117</ArticleId><ArticleId IdType="pubmed">34543501</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghelan Z, Karima S, Ghadami MR, et al. . IgLON5 autoimmunity tested positive in patients with isolated chronic insomnia disease. Clin Exp Immunol. 2022;207(2):237-240. doi. 10.1093/cei/uxab017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cei/uxab017</ArticleId><ArticleId IdType="pmc">PMC8982976</ArticleId><ArticleId IdType="pubmed">35020856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;ter T, M&#xf6;llers FE, Tietz A, et al. , German Network for Research on Autoimmune Encephalitis (GENERATE). Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain. 2022;146(2):600-611. doi. 10.1093/brain/awac090</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac090</ArticleId><ArticleId IdType="pubmed">35259208</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner J, Jelcic I, Schwarz EI, et al. . Anti-IgLON5 disease: a new bulbar-onset motor neuron mimic syndrome. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e962. doi. 10.1212/NXI.0000000000000962</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000962</ArticleId><ArticleId IdType="pmc">PMC8057065</ArticleId><ArticleId IdType="pubmed">33531378</ArticleId></ArticleIdList></Reference><Reference><Citation>Shambrook P, Hesters A, Marois C, et al. . Delayed benefit from aggressive immunotherapy in waxing and waning anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1009. doi. 10.1212/NXI.0000000000001009</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001009</ArticleId><ArticleId IdType="pmc">PMC8192057</ArticleId><ArticleId IdType="pubmed">33986128</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzyka IM, Estephan B. Electrophysiology of cranial nerve testing: trigeminal and facial nerves. J Clin Neurophysiol. 2018;35(1):16-24. doi. 10.1097/WNP.0000000000000445</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNP.0000000000000445</ArticleId><ArticleId IdType="pubmed">29298209</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdugo RJ, Matamala JM, Inui K, et al. . Review of techniques useful for the assessment of sensory small fiber neuropathies: report from an IFCN expert group. Clin Neurophysiol. 2022;136:13-38. doi. 10.1016/j.clinph.2022.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2022.01.002</ArticleId><ArticleId IdType="pubmed">35131635</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975-1978. doi. 10.1016/j.clinph.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo CP, Smoker WR,Weissman JL. MR appearance of trigeminal and hypoglossal motor denervation. AJNR Am J Neuroradiol. 1997;18(7):1375-1383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8338018</ArticleId><ArticleId IdType="pubmed">9282872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghislain B, Rabinstein AA,Braksick SA. Etiologies and utility of diagnostic tests in trigeminal neuropathy. Mayo Clin Proc. 2022;97(7):1318-1325. doi. 10.1016/j.mayocp.2022.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2022.01.006</ArticleId><ArticleId IdType="pubmed">35787858</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaig C, Compta Y. Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Curr Opin Neurol. 2019;32(3):493-499. doi. 10.1097/WCO.0000000000000677</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000677</ArticleId><ArticleId IdType="pubmed">30694925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>